Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of VPRIV in Type 1 Gaucher Disease Extension Study
NCT00391625Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2004
- Primary completion
- Jan 2008
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Primary endpoint: Evaluation of Long Term Safety up to 84 months. Started Sep 2004; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT00391625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391625.